The Glaucoma Book pp 1015-1021 | Cite as

The Glaucoma Book: What Do We Know Now, What Do We Need to Know About Glaucoma?

  • Paul N. Schacknow


What do we know about glaucoma as we approach the end of the first decade of the twenty-first century? What more do we need to know about glaucoma to advance the diagnosis and treatment of our patients? The Glaucoma Book describes the state of the art as practiced by glaucoma subspecialists. In this chapter, I reflect upon the knowledge provided by our contributors and also speculate about what new discoveries loom on the horizon. As glaucoma management is an imperfect science, I would like to indulge my editor’s privilege to offer some educated guesses and opinions about the art of taking care of our patients along with occasional whimsical references.


Retinal Nerve Fiber Layer Glaucoma Patient Angle Closure Glaucoma Retinal Ganglion Cell Selective Laser Trabeculoplasty 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Heinlein RA. Stranger in a Strange Land. New York: Putnam; 1961.Google Scholar
  2. 2.
    Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol. 1996;7(2):93–98.CrossRefPubMedGoogle Scholar
  3. 3.
    Cioffi GA, Latina MA, Schwartz GF. Argon versus selective laser trabeculoplasty. J Glaucoma. 2004;13(2):174–177.CrossRefPubMedGoogle Scholar
  4. 4.
    Latina MA, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol. 2002;13(2):94–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Wise JB. Ten year results of laser trabeculoplasty. Does the laser avoid glaucoma surgery or merely defer it? Eye. 1987;1(Pt 1):45–50.PubMedGoogle Scholar
  6. 6.
    Wise JB. Technical considerations in laser trabeculoplasty. Trans New Orleans Acad Ophthalmol. 1985;33:210–214.PubMedGoogle Scholar
  7. 7.
    Eddy DM, Billings J. The quality of medical evidence: implications for quality of care. Health Aff (Millwood). 1988;7(1):19–32.CrossRefGoogle Scholar
  8. 8.
    Billings J, Eddy D. Physician decision making limited by medical evidence. Bus Health. 1987;5(1):23. 26–28.PubMedGoogle Scholar
  9. 9.
    Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–1720.CrossRefPubMedGoogle Scholar
  10. 10.
    Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123-1129. e1123.CrossRefPubMedGoogle Scholar
  11. 11.
    Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–142.PubMedGoogle Scholar
  12. 12.
    Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(2):205–209.CrossRefPubMedGoogle Scholar
  13. 13.
    Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology. 2008;115(6):934–940.CrossRefPubMedGoogle Scholar
  14. 14.
    Shuba LM, Doan AP, Maley MK, et al. Diurnal fluctuation and concordance of intraocular pressure in glaucoma suspects and normal tension glaucoma patients. J Glaucoma. 2007;16(3):307–312.CrossRefPubMedGoogle Scholar
  15. 15.
    Nakakura S, Nomura Y, Ataka S, Shiraki K. Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical antiglaucoma eye drops. J Glaucoma. 2007;16(2):201–204.CrossRefPubMedGoogle Scholar
  16. 16.
    Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol. 2005;139(2):320–324.CrossRefPubMedGoogle Scholar
  17. 17.
    Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12(3):232–236.CrossRefPubMedGoogle Scholar
  18. 18.
    Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004;26(1):84–91.CrossRefPubMedGoogle Scholar
  19. 19.
    Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17(3):217–222.CrossRefPubMedGoogle Scholar
  20. 20.
    Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49(Suppl 1):S26-S35.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu JH, Gokhale PA, Loving RT, Kripke DF, Weinreb RN. Laboratory assessment of diurnal and nocturnal ocular perfusion pressures in humans. J Ocul Pharmacol Ther. 2003;19(4):291–297.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39(13):2707–2712.PubMedGoogle Scholar
  23. 23.
    Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389–395.CrossRefPubMedGoogle Scholar
  24. 24.
    Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713. discussion 829–830.PubMedGoogle Scholar
  25. 25.
    Goldmann H. Un neuveau tonometre. Bull Soc Ophtalmol Fr. 1955;5:281–292.PubMedGoogle Scholar
  26. 26.
    Pekmezci M, Vo B, Lim AK, et al. The characteristics of glaucoma in Japanese Americans. Arch Ophthalmol. 2009;127(2):167–171.CrossRefPubMedGoogle Scholar
  27. 27.
    Schmidt C. Regulators weigh risks of consumer genetic tests. Nat Biotechnol. 2008;26(2):145–146.CrossRefPubMedGoogle Scholar
  28. 28.
    Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 2001;285(5):540–544.CrossRefPubMedGoogle Scholar
  29. 29.
    Gerard S, Hayes M, Rothstein MA. On the edge of tomorrow: fitting genomics into public health policy. J Law Med Ethics. 2002;30(3 Suppl):173–176.PubMedGoogle Scholar
  30. 30.
    Rothenberg KH, Terry SF. Human genetics. Before it’s too late - addressing fear of genetic information. Science. 2002;297(5579):196–197.CrossRefPubMedGoogle Scholar
  31. 31.
    Henderer JD. Disc damage likelihood scale. Br J Ophthalmol. 2006;90(4):395–396.CrossRefPubMedGoogle Scholar
  32. 32.
    Spaeth GL, Henderer J, Liu C, et al. The disc damage likelihood scale: reproducibility of a new method of estimating the amount of optic nerve damage caused by glaucoma. Trans Am Ophthalmol Soc. 2002;100:181-185. discussion 185–186.PubMedGoogle Scholar
  33. 33.
    Smith CM. Origin and uses of primum non nocere - above all, do no harm! J Clin Pharmacol. 2005;45(4):371–377.CrossRefPubMedGoogle Scholar
  34. 34.
    Rein DB, Wittenborn JS, Lee PP, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology. 2009;116(5):823–832.CrossRefPubMedGoogle Scholar
  35. 35.
    Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982;100(1):135–146.PubMedGoogle Scholar
  36. 36.
    Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99(4):635–649.PubMedGoogle Scholar
  37. 37.
    Quigley HA, Green WR. The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. Ophthalmology. 1979;86(10):1803–1830.PubMedGoogle Scholar
  38. 38.
    Weinreb RN, Friedman DS, Fechtner RD, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol. 2004;138(3):458–467.CrossRefPubMedGoogle Scholar
  39. 39.
    Boland MV, Quigley HA, Lehmann HP. The impact of risk calculation on treatment recommendations made by glaucoma specialists in cases of ocular hypertension. J Glaucoma. 2008;17(8):631–638.CrossRefPubMedGoogle Scholar
  40. 40.
    Mansberger SL, Medeiros FA, Gordon M. Diagnostic tools for calculation of glaucoma risk. Surv Ophthalmol. 2008;53(Suppl 1):S11-S16.CrossRefPubMedGoogle Scholar
  41. 41.
    Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007;114(1):10–19.CrossRefPubMedGoogle Scholar
  42. 42.
    Mansberger SL, Cioffi GA. The probability of glaucoma from ocular hypertension determined by ophthalmologists in comparison to a risk calculator. J Glaucoma. 2006;15(5):426–431.CrossRefPubMedGoogle Scholar
  43. 43.
    Mansberger SL. A risk calculator to determine the probability of glaucoma. J Glaucoma. 2004;13(4):345–347.CrossRefPubMedGoogle Scholar
  44. 44.
    Higginbotham EJ, Richardson TM. Response of exfoliation glaucoma to laser trabeculoplasty. Br J Ophthalmol. 1986;70(11):837–839.CrossRefPubMedGoogle Scholar
  45. 45.
    Sherwood MB, Svedbergh B. Argon laser trabeculoplasty in exfoliation syndrome. Br J Ophthalmol. 1985;69(12):886–890.CrossRefPubMedGoogle Scholar
  46. 46.
    Ritch R, Podos S. Laser trabeculoplasty in the exfoliation syndrome. Bull N Y Acad Med. 1983;59(4):339–344.PubMedGoogle Scholar
  47. 47.
    Logan P, Burke E, Joyce PD, Eustace P. Laser trabeculoplasty in the pseudo-exfoliation syndrome. Trans Ophthalmol Soc U K. 1983;103(Pt 6):586–587.PubMedGoogle Scholar
  48. 48.
    Ritch R, Liebmann J, Robin A, et al. Argon laser trabeculoplasty in pigmentary glaucoma. Ophthalmology. 1993;100(6):909–913.PubMedGoogle Scholar
  49. 49.
    Lehto I. Long-term follow up of argon laser trabeculoplasty in pigmentary glaucoma. Ophthalmic Surg. 1992;23(9):614–617.PubMedGoogle Scholar
  50. 50.
    Lunde MW. Argon laser trabeculoplasty in pigmentary dispersion syndrome with glaucoma. Am J Ophthalmol. 1983;96(6):721–725.PubMedGoogle Scholar
  51. 51.
    Robin AL, Pollack IP. Argon laser trabeculoplasty in secondary forms of open-angle glaucoma. Arch Ophthalmol. 1983;101(3):382–384.PubMedGoogle Scholar
  52. 52.
    Sherwood MB, Migdal CS, Hitchings RA, Sharir M, Zimmerman TJ, Schultz JS. Initial treatment of glaucoma: surgery or medications. Surv Ophthalmol. 1993;37(4):293–305.CrossRefPubMedGoogle Scholar
  53. 53.
    Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968;66(4):673–679.PubMedGoogle Scholar
  54. 54.
    Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;(4):CD002897.Google Scholar
  55. 55.
    Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term followup. Ophthalmology. 2000;107(6):1184–1190.CrossRefPubMedGoogle Scholar
  56. 56.
    Hefetz L, Keren T, Naveh N. Early and late postoperative application of 5-fluorouracil following trabeculectomy in refractory glaucoma. Ophthalmic Surg. 1994;25(10):715–719.PubMedGoogle Scholar
  57. 57.
    Stilma JS. Trabeculectomy with 5-fluorouracil in complicated glaucoma. Klin Oczna. 1993;95(2):81–83.PubMedGoogle Scholar
  58. 58.
    Smith MF, Sherwood MB, Doyle JW, Khaw PT. Results of intraoperative 5-fluorouracil supplementation on trabeculectomy for open-angle glaucoma. Am J Ophthalmol. 1992;114(6):737–741.PubMedGoogle Scholar
  59. 59.
    Wilson RP, Steinmann WC. Use of trabeculectomy with postoperative 5-fluorouracil in patients requiring extremely low intraocular pressure levels to limit further glaucoma progression. Ophthalmology. 1991;98(7):1047–1052.PubMedGoogle Scholar
  60. 60.
    Liebmann JM, Ritch R, Marmor M, Nunez J, Wolner B. Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. Ophthalmology. 1991;98(7):1036–1041.PubMedGoogle Scholar
  61. 61.
    Taniguchi T, Kitazawa Y, Shimizu U. Long-term results of 5-fluorouracil trabeculectomy for primary open-angle glaucoma. Int Ophthalmol. 1989;13(1-2):145–149.CrossRefPubMedGoogle Scholar
  62. 62.
    Kitazawa Y, Taniguchi T, Nakano Y, Shirato S, Yamamoto T. 5-Fluorouracil for trabeculectomy in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1987;225(6):403–405.CrossRefPubMedGoogle Scholar
  63. 63.
    Rauscher FM, Gedde SJ, Schiffman JC, Feuer WJ, Barton K, Lee RK. Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up. Am J Ophthalmol. 2009;147(3):458–466.CrossRefPubMedGoogle Scholar
  64. 64.
    Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol. 2007;143(1):9–22.CrossRefPubMedGoogle Scholar
  65. 65.
    Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol. 2007;143(1):23–31.CrossRefPubMedGoogle Scholar
  66. 66.
    Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK 2nd, Heuer DK, Brandt JD. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005;140(2):275–287.CrossRefPubMedGoogle Scholar
  67. 67.
    Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: circumferential viscodilation and tensioning of Schlemm canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: two-year interim clinical study results. J Cataract Refract Surg. 2009;35(5):814–824.CrossRefPubMedGoogle Scholar
  68. 68.
    Grieshaber MC, Pienaar A, Olivier J, Stegmann R. Channelography: imaging of the aqueous outflow pathway with flexible microcatheter and fluorescein in canaloplasty. Klin Monatsbl Augenheilkd. 2009;226(4):245–248.CrossRefPubMedGoogle Scholar
  69. 69.
    Shingleton B, Tetz M, Korber N. Circumferential viscodilation and tensioning of Schlemm canal (canaloplasty) with temporal clear corneal phacoemulsification cataract surgery for open-angle glaucoma and visually significant cataract: one-year results. J Cataract Refract Surg. 2008;34(3):433–440.CrossRefPubMedGoogle Scholar
  70. 70.
    Kobayashi H, Kobayashi K, Okinami S. A comparison of the intraocular pressure-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C in bilateral open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2003;241(5):359–366.CrossRefPubMedGoogle Scholar
  71. 71.
    Shaarawy T, Nguyen C, Schnyder C, Mermoud A. Five year results of viscocanalostomy. Br J Ophthalmol. 2003;87(4):441–445.CrossRefPubMedGoogle Scholar
  72. 72.
    O'Brart DP, Rowlands E, Islam N, Noury AM. A randomised, prospective study comparing trabeculectomy augmented with antimetabolites with a viscocanalostomy technique for the management of open angle glaucoma uncontrolled by medical therapy. Br J Ophthalmol. 2002;86(7):748–754.CrossRefPubMedGoogle Scholar
  73. 73.
    Ahmed II, Crandall AS. Viscocanalostomy vs trabeculetomy. Ophthalmology. 2002;109(3):411–412.CrossRefPubMedGoogle Scholar
  74. 74.
    Jonescu-Cuypers C, Jacobi P, Konen W, Krieglstein G. Primary viscocanalostomy versus trabeculectomy in white patients with open-angle glaucoma: a randomized clinical trial. Ophthalmology. 2001;108(2):254–258.CrossRefPubMedGoogle Scholar
  75. 75.
    Crandall AS. Nonpenetrating filtering procedures: viscocanalostomy and collagen wick. Semin Ophthalmol. 1999;14(3):189–195.CrossRefPubMedGoogle Scholar
  76. 76.
    Bylsma S. Nonpenetrating deep sclerectomy: collagen implant and viscocanalostomy procedures. Int Ophthalmol Clin. 1999;39(3):103–119.CrossRefPubMedGoogle Scholar
  77. 77.
    Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316–322.CrossRefPubMedGoogle Scholar
  78. 78.
    Carassa RG, Bettin P, Brancato R. Viscocanalostomy: a pilot study. Acta Ophthalmol Scand Suppl. 1998;227:51–52.PubMedGoogle Scholar
  79. 79.
    Godfrey DG, Fellman RL, Neelakantan A. Canal surgery in adult glaucomas. Curr Opin Ophthalmol. 2009;20(2):116–121.CrossRefPubMedGoogle Scholar
  80. 80.
    Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma. 2004;13(3):221–226.CrossRefPubMedGoogle Scholar
  81. 81.
    Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med. 2001;7(3):304–309.CrossRefPubMedGoogle Scholar
  82. 82.
    Diaz-Aleman VT, Anton A, de la Rosa MG, Johnson ZK, McLeod S, Azuara-Blanco A. Detection of visual-field deterioration by Glaucoma Progression Analysis and Threshold Noiseless Trend programs. Br J Ophthalmol. 2009;93(3):322–328.CrossRefPubMedGoogle Scholar
  83. 83.
    Robin AL, Clark AF, Covert DW, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147(1):45–50.CrossRefPubMedGoogle Scholar
  84. 84.
    Minckler D, Baerveldt G, Ramirez MA, et al. Clinical results with the Trabectome, a novel surgical device for treatment of open-angle glaucoma. Trans Am Ophthalmol Soc. 2006;104:40–50.PubMedGoogle Scholar
  85. 85.
    Minckler DS, Baerveldt G, Alfaro MR, Francis BA. Clinical results with the Trabectome for treatment of open-angle glaucoma. Ophthalmology. 2005;112(6):962–967.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Paul N. Schacknow
    • 1
    • 2
  1. 1.Division of OphthalmologyNova Southeastern UniversityFort LauderdaleUSA
  2. 2.Visual Health CenterPalm SpringsUSA

Personalised recommendations